· Event impact
Morgan Stanley highlights Eli Lilly's GLP-1 dominance over Novo Nordisk
Transmission path
Evidence of market share capture and pricing power in the high-growth GLP-1 market can lead to upward revisions of long-term revenue and earnings forecasts for the dominant player.
Market mechanism
Evidence of market share capture and pricing power in the high-growth GLP-1 market can lead to upward revisions of long-term revenue and earnings forecasts for the dominant player.
Extended read
A new research note from Morgan Stanley has given a significant vote of confidence to Eli Lilly in the competitive GLP-1 obesity drug space. The analysis focuses on the international market, where Lilly's drug Mounjaro is demonstrating remarkable strength. Specifically, the drug achieved 10% growth in the key Indian market, even while competing with generic versions of Novo Nordisk's rival drug, Wegovy. According to the investment bank, this performance is part of a broader trend that has resulted in Eli Lilly capturing over 50% of the entire international GLP-1 market. This is a critical development in a therapeutic area projected to be worth nearly $100 billion by the end of the decade. The note attributes Lilly's success to the superior weight-loss efficacy demonstrated by Mounjaro in clinical trials. This clinical advantage appears to be translating directly into commercial dominance, allowing Lilly to win share from its primary competitor, Novo Nordisk, and solidify its leadership position.
Exposed assets
LLY · NVO · VKTX
Continuous event tracking, options routing, and portfolio overlap for this event and the assumptions it moves live inside Market Ontology. Start a trial →